Načítá se...
Cost effectiveness of recombinant factor VIIa for treatment of intracerebral hemorrhage
BACKGROUND: Phase I/II placebo-controlled clinical trials of recombinant Factor VIIa (rFVIIa) suggested that administration of rFVIIa within 4 hours after onset of intracerebral hemorrhage (ICH) is safe, limits ICH growth, and improves outcomes. We sought to determine the cost-effectiveness of rFVII...
Uloženo v:
| Hlavní autoři: | , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2008
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2397434/ https://ncbi.nlm.nih.gov/pubmed/18489750 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2377-8-17 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|